We have located links that may give you full text access.
Bremelanotide for Female Sexual Dysfunctions: Responder Analyses From a Phase 2B Dose-Ranging Study.
Obstetrics and Gynecology 2014 May
INTRODUCTION: Bremelanotide is a novel heptapeptide melanocortin receptor-4 agonist. This study examined its at-home, as-needed subcutaneous self-administration by premenopausal women with female sexual dysfunctions. Key outcomes were subjected to prespecified responder analyses.
METHODS: After 4 weeks of at-home placebo self-dosing (baseline period), premenopausal women with hypoactive sexual desire disorder, female sexual arousal disorder, or both were randomized to 12-week, at-home use of placebo or bremelanotide at 0.75, 1.25, or 1.75 mg. End points included changes from baseline to end of study in the monthly number of satisfying sexual events and in Female Sexual Function Index total score and Female Sexual Distress Scale-Desire/Arousal/Orgasm total score. Analyses of percent of responders were anchored to expert estimates of minimal clinically important differences: +1 for satisfying sexual events, +2.1 for Female Sexual Function Index, and -7 for Female Sexual Distress Scale-Desire/Arousal/Orgasm.
RESULTS: Overall, 327 randomized participants used at-home study drug and provided data (for satisfying sexual events, 324). For placebo and bremelanotide at 0.75 mg, 1.25 mg, 1.75 mg, and 1.25 and 1.75 mg pooled, responder rates were 37%, 38%, 48%, 55%, and 51% for satisfying sexual events; 46%, 45%, 61%, 69%, and 65% on the Female Sexual Function Index; and 45%, 49%, 60%, 69%, and 64% on the Female Sexual Distress Scale-Desire/Arousal/Orgasm. For all three end points, the difference from placebo was statistically significant (P <.05, Cochran-Mantel-Haenszel test) at 1.75 mg and at 1.25 and 1.75 mg pooled.
CONCLUSIONS: Premenopausal women using self-administered subcutaneous bremelanotide for female sexual dysfunctions showed dose-dependent separations from placebo in the percentages of patients reaching expert-determined minimally clinically important differences for three clinically relevant variables with statistical significance compared with placebo for all three responder rates at 1.75 mg and 1.25 mg and 1.75 mg pooled.
METHODS: After 4 weeks of at-home placebo self-dosing (baseline period), premenopausal women with hypoactive sexual desire disorder, female sexual arousal disorder, or both were randomized to 12-week, at-home use of placebo or bremelanotide at 0.75, 1.25, or 1.75 mg. End points included changes from baseline to end of study in the monthly number of satisfying sexual events and in Female Sexual Function Index total score and Female Sexual Distress Scale-Desire/Arousal/Orgasm total score. Analyses of percent of responders were anchored to expert estimates of minimal clinically important differences: +1 for satisfying sexual events, +2.1 for Female Sexual Function Index, and -7 for Female Sexual Distress Scale-Desire/Arousal/Orgasm.
RESULTS: Overall, 327 randomized participants used at-home study drug and provided data (for satisfying sexual events, 324). For placebo and bremelanotide at 0.75 mg, 1.25 mg, 1.75 mg, and 1.25 and 1.75 mg pooled, responder rates were 37%, 38%, 48%, 55%, and 51% for satisfying sexual events; 46%, 45%, 61%, 69%, and 65% on the Female Sexual Function Index; and 45%, 49%, 60%, 69%, and 64% on the Female Sexual Distress Scale-Desire/Arousal/Orgasm. For all three end points, the difference from placebo was statistically significant (P <.05, Cochran-Mantel-Haenszel test) at 1.75 mg and at 1.25 and 1.75 mg pooled.
CONCLUSIONS: Premenopausal women using self-administered subcutaneous bremelanotide for female sexual dysfunctions showed dose-dependent separations from placebo in the percentages of patients reaching expert-determined minimally clinically important differences for three clinically relevant variables with statistical significance compared with placebo for all three responder rates at 1.75 mg and 1.25 mg and 1.75 mg pooled.
Full text links
Related Resources
Trending Papers
Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.Endocrine Reviews 2024 April 28
The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association.Circulation 2024 April 26
British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults.Gut 2024 April 17
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Ventilator Waveforms May Give Clues to Expiratory Muscle Activity.American Journal of Respiratory and Critical Care Medicine 2024 April 25
Systemic lupus erythematosus.Lancet 2024 April 18
Acute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin Short-Term Use.Pharmaceuticals 2024 March 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app